静脈血栓塞栓症（VTE）の疫学分析と予測（～2032年）

主要7市場（米国・フランス・ドイツ・イタリア・スペイン・英国・日本）におけるVTEの診断症例数は、2022年の146万9,547件から2032年に169万608件に達し、AGRで1.50％の増加が予測されています。各国の罹患率、手術率、基本的な人口動向の変化が、市場の主な促進要因となっています。

当レポートでは、主要7市場における静脈血栓塞栓症（VTE）ついて調査分析し、VTEの危険因子、併存疾患、過去の動向などの情報を提供しています。

目次

第1章 静脈血栓塞栓症（VTE）：エグゼクティブサマリー

• 触媒
• 関連レポート
• 今後のレポート

第2章 疫学

• 疾患の背景
• 危険因子と併存疾患
• 世界の過去の動向
• 主要7市場の予測手法
  • 情報源
  • 予測の前提条件と手法
  • PE、DVT、VTEの診断症例
  • DVTの診断症例：解剖学的領域別
  • VTEの診断症例：誘発危険因子別
  • がんを合併したVTEの診断症例
  • 慢性腎臓病（CKD）を合併したVTEの診断症例
  • 診断されたVTE攻撃
  • 1年後と10年後に初めてVTEが再発した症例
  • 医療的に疾患の基準を満たした退院数
  • VTEのリスクのある医療的に疾患の基準を満たした退院数
  • 股関節・膝関節全置換術の数
• 静脈血栓塞栓症（VTE）の疫学予測（2022年～2032年）
  • PEの診断症例
  • DVTの診断症例
  • VTEの診断症例
  • VTEの診断症例：年齢別
  • VTEの診断症例：性別
  • DVTの診断症例：解剖学的領域別
  • VTEの診断症例：誘発危険因子別
  • 1年後と10年後に初めてVTEが再発した診断症例
  • がんを合併したVTEの診断症例
  • CKDを合併したVTEの診断症例
  • 診断されたVTE発作の数
  • VTEのリスクのある医療的に疾患の基準を満たした退院数
  • 膝関節置換術の数
  • 股関節置換術の数
• 考察
  • 疫学予測の考察
  • COVID-19の影響
  • 分析の限界
  • 分析の強み

第3章 付録

List of Tables

List of Tables

• Table 1: Summary of newly added data types
• Table 2: Summary of updated data types
• Table 3: Risk factors and comorbidities for VTE

List of Figures

List of Figures

• Figure 1: 7MM, diagnosed incident cases of VTE, N, both sexes, all ages, 2022 and 2032
• Figure 2: 7MM, number of diagnosed VTE attacks, N, both sexes, all ages, 2022 and 2032
• Figure 3: 7MM, diagnosed incidence of PE, DVT, and VTE, cases per 100,000 population, both sexes, all ages, 2022
• Figure 4: 7MM, sources used to forecast the diagnosed incident cases of PE, DVT, and VTE
• Figure 5: 7MM, sources used to forecast the diagnosed incident cases of DVT by anatomical region
• Figure 6: 7MM, sources used to forecast the diagnosed incident cases of VTE by provoking risk factor
• Figure 7: 7MM, sources used to forecast the diagnosed incident cases of VTE with cancer as a comorbidity
• Figure 8: 7MM, sources used to forecast the diagnosed incident cases of VTE with CKD as a comorbidity
• Figure 9: 7MM, sources used to forecast the diagnosed VTE attacks
• Figure 10: 7MM, sources used to forecast VTE recurrence after one and 10 years
• Figure 11: 7MM, sources used to forecast the number of hospital discharges that meet medically ill criteria and are at risk of VTE
• Figure 12: 7MM, sources used and not used to forecast the primary total knee replacements and revisions, and hip replacements.
• Figure 13: 7MM, diagnosed incident cases of PE, N, both sexes, all ages, 2022
• Figure 14: 7MM, diagnosed incident cases of DVT, N, both sexes, all ages, 2022
• Figure 15: 7MM, diagnosed incident cases of VTE, N, both sexes, all ages, 2022
• Figure 16: 7MM, diagnosed incident cases of VTE by age, N, both sexes, all ages, 2022
• Figure 17: 7MM, diagnosed incident cases of VTE by sex, N, both sexes, all ages, 2022
• Figure 18: 7MM, diagnosed incident cases of DVT by anatomical region, N, all ages, 2022
• Figure 19: 7MM, diagnosed incident cases of VTE by provoking risk factor, N, both sexes, all ages, 2022
• Figure 20: 7MM, first-time recurrent cases of VTE, N, both sexes, all ages, 2022
• Figure 21: 7MM, diagnosed incident cases of VTE with cancer as a comorbidity, N, both sexes, all ages, 2022
• Figure 22: 7MM, diagnosed incident cases of VTE with CKD as a comorbidity, N, both sexes, 2022 and 2032
• Figure 23: 7MM, diagnosed VTE attacks, N, both sexes, all ages, 2022 and 2032
• Figure 24: 7MM, number of medically ill hospital discharges at risk for VTE, N, both sexes, ≥40 years, 2022
• Figure 25: 7MM, total number of knee replacements, N, both sexes, ≥15 years, 2022 and 2032
• Figure 26: 7MM, total number of hip replacements, N, both sexes, ≥15 years, 2022 and 2032

Abstract

Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a potentially fatal condition that impedes blood flow by causing blood clots (thrombosis). VTE can occur in men and women of all ages, with children at very low risk, and adults ages 40 and over at higher risk; this risk level increases with age (Henke et al., 2020). VTE events are highly dangerous and are associated with high rates of mortality and morbidity.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of VTE in the 7MM, from 1,469,547 cases in 2022 to 1,690,608 in 2032, at an annual growth rate (AGR) of 1.50%. The number of VTE attacks is forecast to grow from 1,602,747 in 2022, to 1,848,622 in 2032 in the 7MM, at an AGR of 1.53%. GlobalData epidemiologists also forecast the number of medically ill patients at risk for VTE to increase in the 7MM from 38,508,614 in 2022 to 41,825,735 in 2032. In addition, GlobalData epidemiologists forecast the number of total knee replacements will grow from 1,604,653 in 2022, to 1,834,770 in 2032 and the number of hip replacements will increase from 1,107,902 in 2022, to 1,240,077 in 2032, at an AGR of 1.43% and 1.19%, respectively. GlobalData epidemiologists have identified the predominant drivers of this market to be changes in country-specific incidence and procedure rates, as well as in the underlying demographic trends.

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical trends for VTE in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of PE, DVT, and VTE, as well as the number of VTE attacks, the number of medically ill discharges that are at risk for VTE, the number of primary total knee replacements and revisions, and the number of hip replacements, each of which are segmented by sex and age. Additionally, it includes a forecast for the number of recurrent VTE cases at one and 10 years after the incident event, a breakdown of proximal and distal DVT, unprovoked and provoked VTE, and the number of diagnosed VTE cases with cancer and chronic kidney disease (CKD) as comorbidity. Although not covered in this report, the attack number and rate for PE and DVT can be found in the model, in addition to the medically ill population at risk for VTE receiving any form of prophylaxis.

Reasons to Buy

The venous thromboembolism epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global atrial fibrillation market.
• Quantify patient populations in the global atrial fibrillation market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for atrial fibrillation therapeutics in each of the markets covered.

Table of Contents

Table of Contents

1 Venous Thromboembolism (VTE): Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Diagnosed incident cases of PE, DVT, and VTE
  • 2.4.4 Diagnosed incident cases of DVT by anatomical region
  • 2.4.5 Diagnosed incident cases of VTE by provoking risk factor
  • 2.4.6 Diagnosed incident cases of VTE with cancer as a comorbidity
  • 2.4.7 Diagnosed incident cases of VTE with chronic kidney disease (CKD) as a comorbidity
  • 2.4.8 Diagnosed VTE attacks
  • 2.4.9 Number of one- and 10-year first time recurrent cases of VTE
  • 2.4.10 Number of hospital discharges meeting medically ill criteria
  • 2.4.11 Number of hospital discharges meeting medically ill criteria at risk for VTE
  • 2.4.12 Number of total hip and knee replacements
• 2.5 Epidemiological forecast for venous thromboembolism (VTE) (2022-32)
  • 2.5.1 Diagnosed incident cases of PE
  • 2.5.2 Diagnosed incident cases of DVT
  • 2.5.3 Diagnosed incident cases of VTE
  • 2.5.4 Age-specific diagnosed incident cases of VTE
  • 2.5.5 Sex-specific diagnosed incident cases of VTE
  • 2.5.6 Diagnosed incident cases of DVT by anatomical region
  • 2.5.7 Number of diagnosed incident cases of VTE by provoking risk factor
  • 2.5.8 One- and 10-year first time diagnosed recurrent cases of VTE
  • 2.5.9 Diagnosed incident cases of VTE with cancer as a comorbidity
  • 2.5.10 Diagnosed incident cases of VTE with CKD as a comorbidity
  • 2.5.11 Number of diagnosed VTE attacks
  • 2.5.12 Number of hospital discharges meeting medically ill criteria at risk for VTE
  • 2.5.13 Total number of knee replacements
  • 2.5.14 Total number of hip replacements
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Analysis and Intelligence
  • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
• Contact Us